Male Hypogonadism Treatment Algorithm: A Line-by-Line Therapy Guide

Published May 25, 2026Updated Sep 30, 2026Last reviewed May 25, 2026

9 linked public sourcesEditorial, sourcing, and corrections policy

Treatment for male hypogonadism starts with confirming the diagnosis, identifying the cause, and establishing fertility goals. Those decisions determine whether the next step is treatment of a reversible contributor, stimulation of the body's own hormone production, or testosterone replacement. The options are branches in a treatment pathway, rather than a ladder every patient must climb. [1,2]

Step 1: Confirm that symptoms and laboratory results agree

Low libido, fewer spontaneous erections, and other compatible symptoms are assessed alongside repeat early-morning testosterone measurements. The American Urological Association uses total testosterone below 300 ng/dL as a reasonable diagnostic cutoff, with two separate early-morning tests. [1]

The Endocrine Society emphasizes consistently low results, appropriate laboratory methods, and symptoms. Its July 2026 statement reiterates the need for at least two morning fasting tests and evaluation of other causes of low energy, libido, or mood. A single result during illness does not establish a long-term treatment plan. [2]

The appointment should resolve three questions:

Were both samples collected under appropriate conditions?
Are the symptoms consistent with testosterone deficiency?
Is additional testing needed to identify the cause?

Step 2: Identify where the hormone pathway is affected

LH and FSH help distinguish testicular from hypothalamic-pituitary causes. [3]

Pattern	What it suggests	Why it changes treatment
Low testosterone with elevated LH/FSH	Primary hypogonadism, originating in the testes	Increasing the hormonal signal may not restore testicular function.
Low testosterone with low or inappropriately normal LH/FSH	Secondary hypogonadism, involving hypothalamic-pituitary signaling	Treating the cause or replacing gonadotropin signals may be useful.

Prolactin testing and pituitary assessment are selected from the history and hormone pattern. An unexplained abnormality should be investigated rather than treated solely by raising the testosterone number. [3]

Step 3: Address reversible contributors

Weight-related hormone suppression and medicines such as opioids or corticosteroids deserve review. The Endocrine Society's 2026 statement identifies weight loss as the usual first treatment when excess weight is the identified contributor. [2]

This does not mean a man with established testicular or pituitary disease must complete an arbitrary three-month lifestyle trial before receiving treatment. The cause, symptoms, and goals determine timing. Sleep apnea and other relevant health problems are also addressed as part of the treatment assessment. [3]

Step 4: Choose the fertility pathway before starting testosterone

Exogenous testosterone can suppress sperm production. The AUA/ASRM male-infertility guideline advises against testosterone monotherapy when current or future fertility is a goal. [4]

For selected infertile men with low testosterone, specialist options include hCG, selective estrogen receptor modulators such as clomiphene, and other cause-directed treatment. hCG stimulates testosterone production through the LH receptor. In hypogonadotropic hypogonadism, FSH may also be needed to support sperm production. A higher blood testosterone result alone does not establish that fertility has recovered. [4]

Clomiphene works through the hypothalamic-pituitary pathway. These approaches depend on the underlying cause and remaining testicular function. They are not interchangeable treatments for every form of hypogonadism.

Step 5: Select testosterone replacement when it fits the diagnosis

For a man with confirmed symptomatic deficiency whose treatment plan favors replacement, formulation choice depends on dosing preference, cost, absorption, and follow-up needs. [1]

Gels require daily application. Shorter-acting injections have a different dosing rhythm and can produce peaks and troughs. Longer-acting injections, nasal preparations, and pellets offer other schedules; availability and product instructions vary. The timing of a follow-up testosterone blood draw must match the preparation being used. [5]

Product-specific instructions determine how each formulation is used. For example, topical testosterone must be applied in a way that prevents transfer to other people. Aveed injections have their own administration and observation requirements. [5,6]

What improvement should treatment target?

In the Testosterone Trials, 790 men aged 65 or older with low testosterone received testosterone gel or placebo for one year. Testosterone improved sexual activity, desire, and erectile function, with some improvement in mood. It did not improve the trial's primary vitality outcome. [7]

The practical measure of success is improvement in the symptoms being treated alongside an appropriate testosterone level. Persistent fatigue despite a corrected level calls for reassessment of its cause, rather than assuming more testosterone is the answer.

Monitoring and treatment adjustments

The European Association of Urology recommends testosterone and hematocrit checks at three, six, and twelve months after starting therapy, then annually. Hematocrit above 54% requires treatment adjustment or withdrawal, with venesection when indicated. Once it normalizes, a lower dose or a different formulation may be considered. [5]

A baseline hematocrit around 50% is a reason to investigate before treatment; it should not be described as the same threshold used for intervention during therapy. [1]

For men undergoing prostate monitoring, the Endocrine Society recommends assessment before treatment and during the first year. A confirmed PSA increase greater than 1.4 ng/mL above baseline during that year, a confirmed PSA above 4 ng/mL, or an abnormal examination warrants urological assessment. [3]

Pretreatment assessment also includes breast or prostate cancer, untreated severe sleep apnea, uncontrolled heart failure, and unevaluated prostate abnormalities. These findings change the treatment decision. [3]

What TRAVERSE actually found

TRAVERSE randomized 5,246 men with hypogonadism and existing or high cardiovascular risk to testosterone gel or placebo. Major cardiovascular events occurred in 7.0% and 7.3%, respectively, over a mean follow-up of 33 months. Testosterone met the trial's criterion for noninferiority for that endpoint. [8]

That result should be described precisely as a finding about cardiovascular death, nonfatal heart attack, and nonfatal stroke in the studied population. Hematocrit is a separate part of follow-up because testosterone stimulates red blood cell production. The monitoring plan remains part of treatment regardless of the cardiovascular trial result. [5]

Do add-on medicines belong in every TRT plan?

No. A new symptom or abnormal result first calls for review of the diagnosis, dose, formulation, and timing of testing. Aromatase inhibitors and hCG have selected uses, especially in reproductive medicine; they are not an automatic next stage after testosterone replacement. [4]

In a one-year randomized trial in older men with low testosterone, anastrozole increased testosterone but reduced spine bone mineral density. That finding is relevant when considering an aromatase inhibitor solely to change a laboratory number. [9]

References

Evidence overview for Male Hypogonadism Treatment Algorithm: A Line-by-Line Therapy Guide